Glenmark Life Sciences Ltd
NSE:GLS
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
623.25
1 310.9
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one GLS stock under the Base Case scenario is 715.71 INR. Compared to the current market price of 1 045.65 INR, Glenmark Life Sciences Ltd is Overvalued by 32%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Glenmark Life Sciences Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for GLS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Glenmark Life Sciences Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Glenmark Life Sciences Ltd
Balance Sheet Decomposition
Glenmark Life Sciences Ltd
Current Assets | 21B |
Cash & Short-Term Investments | 5.3B |
Receivables | 7.8B |
Other Current Assets | 7.9B |
Non-Current Assets | 9.9B |
Long-Term Investments | 111.2m |
PP&E | 9.5B |
Intangibles | 172.7m |
Other Non-Current Assets | 152.9m |
Current Liabilities | 4.6B |
Accounts Payable | 4B |
Accrued Liabilities | 138.5m |
Other Current Liabilities | 517.2m |
Non-Current Liabilities | 826.5m |
Long-Term Debt | 133.8m |
Other Non-Current Liabilities | 692.7m |
Earnings Waterfall
Glenmark Life Sciences Ltd
Revenue
|
22B
INR
|
Cost of Revenue
|
-9.9B
INR
|
Gross Profit
|
12.1B
INR
|
Operating Expenses
|
-6.6B
INR
|
Operating Income
|
5.5B
INR
|
Other Expenses
|
-1.3B
INR
|
Net Income
|
4.2B
INR
|
Free Cash Flow Analysis
Glenmark Life Sciences Ltd
INR | |
Free Cash Flow | INR |
GLS Profitability Score
Profitability Due Diligence
Glenmark Life Sciences Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Glenmark Life Sciences Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
GLS Solvency Score
Solvency Due Diligence
Glenmark Life Sciences Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Glenmark Life Sciences Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GLS Price Targets Summary
Glenmark Life Sciences Ltd
According to Wall Street analysts, the average 1-year price target for GLS is 1 102.11 INR with a low forecast of 797.9 INR and a high forecast of 1 359.75 INR.
Dividends
Current shareholder yield for GLS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
GLS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Solapur, Maharashtra. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.
Contact
IPO
Employees
Officers
The intrinsic value of one GLS stock under the Base Case scenario is 715.71 INR.
Compared to the current market price of 1 045.65 INR, Glenmark Life Sciences Ltd is Overvalued by 32%.